2010 Annual Meeting | Therapy Program: Multiple Sclerosis

Date Thursday 04/15/10

Time 07:00 PM - 09:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Therapy Program

Director(s) Edward Fox, MD, PhD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with the indications and risks associated with approved disease-modifying agents in clinically isolated syndromes and relapsing-remitting multiple sclerosis and have a clear idea of which drugs in late-stage clinical trials show promise for patients.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic, Interactive

Event Timeline
06:45 PM - 09:00 PM		Break
07:00 PM - 07:05 PM		Introduction Edward Fox, MD, PhD, FAAN
07:05 PM - 07:30 PM		Clinically Isolated Syndrome–Treat or Wait? Corey C. Ford, MD, PhD, FAAN
07:30 PM - 08:00 PM		Identification and Management of Treatment Failures Clyde E. Markowitz, MD
08:00 PM - 08:25 PM		Emerging Oral MS Therapies Harold Moses, MD
08:25 PM - 08:50 PM		Emerging Mononclonal Antibody MS Therapies Edward Fox, MD, PhD, FAAN
08:50 PM - 09:00 PM		Questions and Answers

Faculty Disclosures
Corey C. Ford, MD, PhD, FAAN	No disclosure on file
Edward Fox, MD, PhD, FAAN	Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Fox has received research support from Biogen. The institution of Dr. Fox has received research support from Genentech. The institution of Dr. Fox has received research support from Celgene - BMS. The institution of Dr. Fox has received research support from Chugai. The institution of Dr. Fox has received research support from Novartis. The institution of Dr. Fox has received research support from EMD-Serono. The institution of Dr. Fox has received research support from TG Therapeutics. The institution of Dr. Fox has received research support from AbbVie. The institution of Dr. Fox has received research support from Sanofi Genzyme. The institution of Dr. Fox has received research support from AbbVie.
Clyde E. Markowitz, MD	No disclosure on file
Harold Moses, MD	No disclosure on file

��ɫ��

��ɫ��